SCHEMBL29973257

SCHEMBL29973257

CN[C@H](C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)O)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.43
CTSS P25774 4/20 0.42
CTSK P43235 4/20 0.42
ECE1 P42892 2/20 0.38
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
MMP1 P03956 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
ACE P12821 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15653266 0.89 CYP2D6 (0.43) CYP2D6CTSSCTSKMMP1CA1
SCHEMBL26010069 0.80 CTSK (0.41) CYP2D6CTSSCTSKMMP1CTSL
SCHEMBL29709624 0.80 MME (0.45) ECE1CA2
SCHEMBL12570554 0.80 CYP2D6 (0.42) CYP2D6CTSSCTSKCA1CA2
SCHEMBL10048032 0.80 CYP2D6 (0.42) CYP2D6CTSSCTSKCA1CA2
SCHEMBL13660687 0.80 CYP2D6 (0.42) CYP2D6CTSSCTSKCA1CA2
SCHEMBL30134419 0.78 FNTA (0.40) CYP2D6CTSSCTSKFNTAFNTB
SCHEMBL16945887 0.78 GNPAT (0.47) CYP2D6CTSSCTSKECE1MMP1
SCHEMBL16945947 0.78 GNPAT (0.47) CYP2D6CTSSCTSKECE1MMP1
SCHEMBL16945945 0.78 GNPAT (0.47) CYP2D6CTSSCTSKECE1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331072-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 US disclosed
US-20250188116-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-12 US disclosed
CN-119143631-A Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound 中外制药株式会社 2024-12-17 CN disclosed
CN-113056475-B Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound 中外制药株式会社 2024-09-24 CN disclosed
US-20230303619-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-28 US disclosed
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-22 US disclosed
US-20230056969-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-23 US disclosed
EP-4083051-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound VIP, PEPD, MLN CYP2D6 4686/4885CTSS 580/4885CTSK 423/4885
US-12331072-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound VIP, PEPD, MLN CYP2D6 4686/4885CTSS 580/4885CTSK 423/4885
US-20230056969-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND VIP, NGLY1, NPPA CYP2D6 4754/4885CTSS 231/4885CTSK 214/4885
US-20230303619-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND VIP, PEPD, MLN CYP2D6 4686/4885CTSS 580/4885CTSK 423/4885
US-20250188116-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND VIP, PEPD, MLN CYP2D6 4686/4885CTSS 580/4885CTSK 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.